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Cisplatin is one of the first line anti-cancer drugs prescribed for treatment of solid tumors;
however, the chemotherapeutic drug resistance is still a major obstacle of cisplatin in
treating cancers. Yu Ping Feng San (YPFS), a well-known ancient Chinese herbal
combination formula consisting of Astragali Radix, Atractylodis Macrocephalae
Rhizoma and Saposhnikoviae Radix, is prescribed as a herbal decoction to treat
immune disorders in clinic. To understand the fast-onset action of YPFS as an anti-
cancer drug to fight against the drug resistance of cisplatin, we provided detailed analyses
of intracellular cisplatin accumulation, cell viability, and expressions and activities of ATP-
binding cassette transporters and glutathione S-transferases (GSTs) in YPFS-treated lung
cancer cell lines. In cultured A549 or its cisplatin-resistance A549/DDP cells, application of
YPFS increased accumulation of intracellular cisplatin, resulting in lower cell viability. In
parallel, the activities and expressions of ATP-binding cassette transporters and GSTs
were down-regulated in the presence of YPFS. The expression of p65 subunit of NF-κB
complex was reduced by treating the cultures with YPFS, leading to a high ratio of Bax/Bcl-
2, i.e. increasing the rate of cell death. Prim-O-glucosylcimifugin, one of the abundant
ingredients in YPFS, modulated the activity of GSTs, and then elevated cisplatin
accumulation, resulting in increased cell apoptosis. The present result supports the
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notion of YPFS in reversing drug resistance of cisplatin in lung cancer cells by elevating of
intracellular cisplatin, and the underlying mechanism may be down regulating the activities
and expressions of ATP-binding cassette transporters and GSTs.
Keywords: yu ping feng san, cisplatin, GSTs, efflux transporters, anti-multidrug resistance, prim-o-
glucosylcimifugin
INTRODUCTION
Lung cancer is the most diagnosed cancer with overwhelming
mortality among all types of cancers, which can be classified into
non-small-cell lung cancer (NSCLC) and small-cell lung cancer
(SCLC). NSCLC accounts for over 85% of total lung cancer
incidents (Siegel et al., 2014). In cancer chemotherapy, most of
the anti-cancer drugs exhibit resistance by cancer cells, and which
results in failure of chemotherapy and/or tumor recurrence.
Multidrug resistance (MDR) is a major impediment to
chemotherapeutic efficacy in cancer patients. At the beginning
of chemotherapeutic treatment, intrinsic drug resistance is
causing unresponsiveness of cancer cell to chemotherapy. The
acquired resistance arises in recurrence of tumor, and which
thereafter displays resistance to a broad range of structural and
functional diverse chemicals. The transformation of tumor with
MDR could be mediated by various parameters, e.g. regulating
drug efflux/influx, changing drug detoxification system,
expressing gene/protein in apoptosis and drug distribution
(Larsen et al., 2000; Baird and Kaye, 2003).
Cisplatin, a platinum-based anti-cancer drug with known
action mechanism and at low cost, has been widely used in
chemotherapy for a variety of tumors. The cytotoxic action of
cisplatin is to interact with DNA forming DNA adducts, and
ultimately triggers cell apoptosis (Siddik, 2003). However, the
clinical usage of cisplatin is limited by its severe dose-limiting side
effect and MDR (Chen et al., 2019). Combining cisplatin with
other anti-cancer drugs during chemotherapy therefore is the
cornerstone in treating various cancers, e.g. lung cancer. Tackling
the reason of cisplatin-resistance in cancer is of great significance.
Glutathione S-transferases (GSTs), a large family of isozymes,
are multi-functional enzymes having crucial roles in cellular
detoxification and oxidative stress tolerance. The most
important members of GSTs are GSTPi1, GSTM1, GSTM2,
and GSA1 (Ekhart et al., 2009). GSTs catalyze the nucleophilic
addition of glutathione (GSH) to non-polar exogenous, e.g.
cisplatin, yielding water-soluble conjugates. The mono-
hydrated form of cisplatin is a highly reactive species, and
which is a rate-limiting step to interact with endogenous
nucleophiles, e.g. GSH, forming a variety of non-toxic cisplatin
conjugates (Siddik, 2003). The GSH-conjugated cisplatin can be
transported by multidrug resistance associated protein 2 (MRP2),
as a result of low bioavailability, leading to cisplatin-resistance
(Siddik, 2003; Wen et al., 2014). The upregulation and
hyperactivation of these GSTs could enhance the catalytic
detoxification of anti-cancer drugs and modulate apoptotic
signaling, and indeed the level of GSTs is being considered as
one of the major causes of MDR in cancer cells (Singh, 2015).
Glutathione metabolic signaling leads to a decrease of cisplatin
being accumulated and developed resistance. Therefore, the
suppression of GST activity is expected to enhance the efficacy
of cytotoxic agents (Zou et al., 2019).
P-gp (P-glycoprotein), BCRP (breast cancer resistance protein)
and MRPs (multidrug resistance associated proteins, including
MRP1, MRP2, and MRP3) are known members of ATP-binding
cassette (ABC) efflux transporters. Most of the anti-cancer drugs are
substrates of these transporters that efflux transport the drugs
resulting in an ATP-dependent decrease of intracellular drug
accumulation. Thus, MDR is usually considered as a severe
consequence of overexpression and hyperactive of ATP-binding
cassette efflux transporters (Leslie et al., 2005). An inhibition of efflux
transporter is expected to be one of the effective ways to re-sensitize
MDR cells during chemotherapy.
Yu Ping Feng San (YPFS) is an ancient Chinese herbal
decoction described in “Dan Xi Xin Fa” by Zhu Danxi (A.D.
1279–1368) (Wilcox, 2004), one of the four great masters in using
herbal treatments on damp-heat and yin-insufficiency conditions
in traditional Chinese medicine (TCM) during the Jin-Yuan
Dynastic period. YPFS composes of Astragali Radix [AR,
Huangqi, the root of Astragalus membranaceus (Fisch.) Bunge
or Astragalus membranaceus (Fisch.) Bunge var. mongholicus
(Bunge) P. K. Hsiao], Atractylodis Macrocephalae Rhizoma
(AMR, Baizhu, the rhizomes of Atractylodes macrocephala
Koidz.) and Saposhnikoviae Radix [SR, Fangfeng, the roots of
Saposhnikovia divaricata (Turcz.) Schischk.] in a weight ratio of
1:2:1 (Du et al., 2013). Our previous study demonstrated that
YPFS modulated inflammatory cytokines and enzymes to exert
immune functions (Du et al., 2013; Du et al., 2014; Du et al.,
2015), and regulated p62/TRAF6 signaling and WT1-mediated
stabilization on mTOR/AKT axis in both cell and animal models
(Du, 2014; Lou et al., 2016; Lou et al., 2018). The underlying
mechanism of anti-drug resistance efficacy of YPFS in a fast-onset
manner however has not yet been elucidated. Here, we
demonstrated the fast action of YPFS in reversing the
cisplatin-resistance in cultured adeno-carcinomic human
alveolar basal epithelial cells (A549) and its cisplatin-resistance
cells (A549-DDP). In parallel, the activities of GSTs and ATP-
binding cassette efflux transporters were measured, and the
apoptotic related targets, i.e. p65, Bax and Bcl-2, were
investigated here. The active role of prim-O-glucosylcimifugin,
an identified active ingredient in YPFS, in fighting against
cisplatin resistance was further revealed.
MATERIALS AND METHODS
Herbal Preparation
The roots of A. membranaceus var. mongholicus (AR), the
rhizomes of A. macrocephala (AMR) and the roots of S.
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divaricata (SR), purchased from medicinal herbal market in
Puning City, Guangdong Province, were authenticated
morphologically by one of the authors, Dr. Du. The herbs,
standardized and met the quality control standard of Chinese
Pharmacopoeia, were utilized for YPFS preparation. The
corresponding voucher specimens, voucher AR18-01, voucher
AMR18-01, and voucher SR18-01, in the form of whole plants,
were deposited at Room 710 of Like Building at Hanshan Normal
University. No specific permission was required for the location
or activity during the collection of raw material. The location was
not privately owned or protected. The herbal extracts of YPFS
were prepared as the method established by our previously study
(Du et al., 2013). Briefly, the herbs of AR, AMR and SR in a weight
ratio of 1:2:1 were boiled together in eight volumes of water (v/w)
by moderate heating for 2 h, and then the herbal residues were re-
boiled in six volumes of water for 1 h. All decoctions were
combined, filtered and lyophilized, and then stored at 4°C.
Here, a standardized YPFS was calibrated by a method
described before (Du et al., 2013). A gradient elution of
5–95% acetonitrile at 0–80 min and 210 nm detection
wavelength were set as an optimized parameter. The herbal
extracts were dissolved in water at 50 mg/ml for 30 min
sonication, and which were filtered through 0.22 μm filtration
membrane before high performance liquid chromatography
(HPLC) injection. SB-C18 analytical HPLC column was used
for separation of YPFS in an Agilent rapid resolution HPLC 1200
system. The amount of chemicals in YPFS was then determined,
meeting the minimum requirements of a standardized YPFS
according to previous study (Du et al., 2013).
Chemicals
The chemical markers (purity ≥98%) were purchased from Sichuan
Victory Biological Technology Co., Ltd. Materials for tissue culture
were purchased from Invitrogen (Carlsbad, CA). The antibodies
were obtained from Abcam (Cambridge, United Kingdom), Absin
(Absin Bioscience Co., Ltd.) and Invitrogen. BDGentestTMATPase
assay kit was purchased from BD Bioscience (San Jose, CA). GST
activity assay kit, BCA protein assay kit, A549 cell lines were
purchased from Dingguo Changsheng Biotechnology Ltd.
(Guangzhou, China). A549-DDP (cisplatin resistance) cell was
purchased from Fudan IBS cell bank (FDCC). TRIzol™ Reagent,
High-Capacity cDNA Reverse Transcription Kits, PowerUp™
SYBR™ Green Master Mix, Pierce® Fast Western Blot Kit, and
PVDF Transfer Membrane were purchased from ThermoFisher
Scientific (Guangzhou, China).Materials that not specified here were
purchased from Sigma-Aldrich. (St. Louis, MO), ThermoFisher
Scientific, Merck (Whitehouse Station, NJ), Dingguo and Xinjing
Biotechnology.
Cell Culture
A549 and A549-DDP cells were cultured in RPMI-1600
supplemented with 10% fetal bovine serum and 100 U/ml of
penicillin and 100 μg/ml of streptomycin, and which were
maintained at 37°C in a humidified atmosphere of 5% CO2.
A549-DDP cells were maintained in the presence of 2.5 µM
cisplatin, which were withdrawn for two generations before
drug treatment. Ninety percent confluency of cells grown in
the logarithmic phase were washed with PBS twice, and then
cells were harvested by using 0.25% trypsin-EDTA about 40 s for
cell dissociation before the sub-culture. After seeding, the cells
were cultured overnight prior to drug treatment.
Cellular Accumulation of Cisplatin
Cells were plated in 100-mm culture plates and cultured to 90%
confluent, then the medium was replaced with fresh medium
containing 80 µM cisplatin in the absence or presence of YPFS at
concentrations of 0–3 mg/ml, or MK571 at concentrations of
0–12 μM, or prim-O-glucosylcimifugin at 0–10 μM, for 3 h before
the measurement of cisplatin being accumulated inside the cells.
After 3 h of drug treatment, the cell monolayers were washed
three times with PBS. The cells were then harvested by a scraper
and were removed from plates by PBS. The cell suspension was
centrifuged at 1,000× g for 3 min at 25°C. Then, the cell pellets
were lyophilized, and the total amount of the protein was
measured. The lyophilized cell pellets were mineralized in
500 µl 70% HNO3 spiking with 40 μg/L cadmium at 80°C for
2 h, and then diluted with 2.5 ml H2O. Thermo Scientific MaxQ
4,000 benchtop refrigerated shaker was used for sample digestion.
Platinum determination was performed with inductively coupled
plasma-optical emission spectroscopy (ICP-OES). The amount of
platinum was corrected in respect to cadmium signal and total
protein.
Cell Viability Assay
Five thousand cells per well were seeded in 96-well plate
overnight, and then treated with various concentration of
cisplatin, or 2.5 µM cisplatin in present or absent of YPFS at
concentrations of 0–3 mg/ml, or prim-O-glucosylcimifugin at
0–10 µM for 24 h in cultured A549 or A549-DDP cells. The
group without drug treatment was taken as a control.
Subsequently, 10 µl MTT (5 mg/ml) was added into the
culture for another 1 h. Then, the medium was removed, and
DMSO solvent was added to extract purple formazan. The
absorbance at 570 nm was measured. The percentage of cell
apoptosis was calculated by the means of optical density (OD)
in the indicated group in six repeats. Cell apoptosis rate (%) 
1—(ODtreatment group/ODcontrol group) × 100%.
Glutathione S-transferase Activity
Forty thousand cells per well were seeded in 12-well plate
overnight, and then were treated with YPFS at
concentrations of 0–3 mg/ml, or prim-O-glucosylcimifugin at
concentrations of 0–10 µM. After 48 h of culture, the cells were
then washed and scraped with pre-chilled PBS at a ratio of cell
number (106): PBS (µl)  1 : 300–500. The collected cells were
then lyzed by ultrasonic breaker in ice water bath for 2 s
sonication and 3 s interval within 5 min of total time under
200 W, and which were centrifuged at 10,000 × g for 10 min. The
supernatant was preserved on ice. In accord to Elabscience GST
activity assay kit, the reagent three buffer and cuvette were pre-
heated at 37°C for 10 min and spectrophotometer was set to zero
with double distilled water. One hundred μl cell lysate was added
to mix buffer, according to instruction. Absorbance at 340 nm at
20 s (A1) and 320 s (A2) were obtained, respectively. ΔA was
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obtained from A2 subtracted A1. One unit of GST activity was
defined as the amount of GST in 1 mg of tissue protein that
catalyzes the combination of 1 µM of CDNB and GSH at 37°C
per min.
GSTactivity (U/mL)  ΔA/(ε × d) × 106 ÷ t × (V1/V2) × f ÷Cpr,
(1)
ε: molar extinction coefficient of the product, 9.6 × 103
L/mol/cm,
d: optical path of the cuvette, 1 cm,
106: 1 mol  106 μmol,
V1: the total volume of the reaction system, 1.1 ml,
V2: the volume of sample added into the reaction system,
0.1 ml,
T: reaction time, 5 min,
Cpr: concentration of protein in sample, mg/mL.
For investigating direct effect of YPFS on GST activity, the
lysates from non-treated cells were obtained and incubated with
YPFS for 5 min at 37°C, and then GST activity was assayed as
described above in parallel.
ATPase Activity
The plasma membrane was diluted to 1 mg/ml by using the assay
buffer. Then, the membrane was pre-incubated with or without
YPFS about 5 min. Sodium orthovanadate (NaOV) inhibits
ATPase by trapping Mg2+ADP in the nucleotide-binding sites.
Thus, each identical reaction mixture containing NaOV (0.25 mM
for P-gp, 1 mM for BCRP,MRP1 andMRP2, 3 mM forMRP3) was
assayed for further 10 min in parallel. Probe substrates, i.e. 20 µM
verapamil for P-gp 10 µM sulfasalazine for BCRP, 10mM (NEM:
GSH) complex for MRP1, 1 mM probenecid for MRP2 and 50 µM
benzbromarone for MRP3, accompany with 4 mM Mg2+ATP
solution, were added to activate ATPase activity, separately. The
corresponding incubation time for activation of ATPase activity
assay was 10min for BCRP, 20 min for P-gp, 40 min for MRP2,
60 min for MRP1 and MRP3, separately. Here, ATPase activity
measured with NaOV represented non-ATPase activity, and which
was subtracted from the total activity measured in the sample to
yield ATPase activity. The reaction was stopped by addition of 10%
SDS, and liberation of inorganic phosphate was detected by
colorimetric reaction with ascorbic acid in ammonium
molybdate solution (Drueckes et al., 1995).
Western Blot Analysis
Cells were washed with pre-chilled PBS, three times, lyzed with
RIPA and vortexed for 10 min, and then centrifuged at 10,000 × g
for 10 min at 4°C. Total protein was measured by BCA protein
assay kit and diluted to 1 mg/ml. Thirty μg protein was subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and then were transferred to a PVDF membrane
from polyacrylamide gels at 90 mA for 20 h in 1 × transfer buffer
containing 25 mM Tris, 192 mM glycine, 15% ethanol and 0.1%
SDS. The membrane was blocked with 5% non-fat milk in 20 mM
Tris base, 137 mM NaCl, 0.1% Tween-20, pH 7.6 (TBS-T) for 1 h
at 4°C followed by incubation with primary antibody overnight
with gentle agitation. The dilutions for all primary antibodies are
at 1:1,000, and 1:5,000 for GAPDH. After intensive washing with
TBS-T, horseradish peroxidase (HRP)-conjugated goat anti-
mouse, or anti-rabbit secondary antibody, with 1:5,000
dilution was added and incubated for 2 h at 4°C. The protein
signal was developed by ECL method and measured by using a
FluorChem HD2 system (Alpha Innotech).
Ribonucleic Acid (RNA) Extraction and
Quantitative Real-Time Polymerase Chain
Reaction (PCR)
Total RNA was isolated from A549/A549-DDP cells using TRIzol
(Invitrogen). Synthesis of cDNA was performed using 2 μg of
total RNA using high capacity cDNA Reverse Transcription Kits.
Intron-spanning primer was designed to amplify by real-time
quantitative PCR. The sequences were listed as follow: Bax: 5′-
TGA CGG CAA CTT CAA CTG-3′, 3′-CTT CCA GAT GGT
FIGURE 1 | YPFS increases intracellular platinum in cultured A549 and
A549-DDP cells. Cultured A549 and A549-DDP cells (500,000) were plated in
a 100-mm culture plate and cultured to 90% confluent. Then, cells were
challenged with 2.5 µM cisplatin (non-toxic dose) and MK 571 (A) or
YPFS extract (B) for 3 h. After washing, the collected cells were digested with
500 μl 70% HNO3 spiked with 40 μg/ml cadmium for 2 h and adjusted with
water to 3 ml and subjected to ICP-OES analysis. Values are normalized with
total protein and cadmium signal, expressed as % of increase as compared
with control group (no drug), in mean ± SEM, n  3. * or #, p < 0.05, ** or ##, p <
0.01, *** or ###, p < 0.001.
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GAG TGA G-5′, Bcl-2: 5′-TGT GGA TGA CTG AGT ACC T-3′,
3′-CAG AGA CAG CCA GGA GAA- 5′, GSTPi1: 5′-TAC CAG
TCC AAT ACC ATC CT-3′, 3′- GCC TTC ACA TAG TCA TCC
TT-5′, GSTM1: 5′-GAC GCT CCT GAT TAT GAC A-3′, 3′-
CAC ACG AAT CTT CTC CTC TT-5′, GAPDH: 5′-TAT GAC
AAC AGC CTC AAG AT-3′, 3′-AGT CCT TCC ACG ATA
CCA-5’. Quantitative real-time PCR analysis was performed
with 2 × PowerUp™ SYBR™ Green Master Mix, using Roche
LightCycler® 96 Detection System. The quantitative real-time
PCR parameter was as follows: 2 min at 50°C for UDG activation
and 2min at 95°C for Dual-Lock™ DNA Taq polymerase enzyme to
initiate hot-start mechanism, then 40 cycles of denaturation at 95°C
for 15 s, annealing at 55°C for 15 s, and extension at 72°C for 1 min.
The gene expression level was normalized to that of GAPDH in each
sample and calculated as the threshold cycle (CT) value in each
sample, divided by the CT value in each reference.
Statistical Analysis
Data are presented as Mean ± SEM (standard error of mean).
Statistical analysis was performed with SPSS 22.0 statistical
software (SPSS, Chicago, IL). The statistical difference among
groups was analyzed by using one way-ANOVA. p value less than
0.05 was considered as a statistically significant difference.
RESULTS
Yu Ping Feng San Increases Intracellular
Cisplatin
A standardized YPFS was prepared, as described in our previous
study (Du et al., 2013). A typical HPLC profile of YPFS containing
various known chemical markers, as well as those of single herbs
AR, AMR and SR, were shown (Supplementary figure S1). Here,
1 g of prepared YPFS contained 0.533 mg/g calycosin-7-O-β-D-
glucoside, 0.251 mg/g calycosin, 0.701 mg/g ononin, 0.378 mg/g
formononetin, 0.145mg/g astragaloside IV, 0.120mg/g astragaloside
III, 0.086 mg/g astragaloside II, 0.042 mg/g atractylenolide
I, 0.073 mg/g atractylenolide II, 0.382 mg/g atractylenolide
III, 0.882 mg/g prim-O-glucosylcimifugin, 0.588 mg/g 5-O-
methylvisammioside, 0.516 mg/g cimifugin and 0.307 mg/g
sec-O-glucosylhamaudol. The amounts of chosen marker
chemicals in the prepared YPFS met the chemical parameters
established before (Du et al., 2013).
In contrast to A549 cells, A549/DDP cells showed drug
resistance to cisplatin. Our previous study has shown that
YPFS could increase intracellular accumulation of the active
ingredients, i.e. calycosin and formononetin, within 3 h in the
cultures: these compounds were the substrates of efflux
transporters, as that of cisplatin (Du, 2014). Thus, we
hypothesized that the synergy of YPFS with cisplatin in
inducing toxicity of cancer cells could be related to GST and
efflux drug transporter. To test this hypothesis, an ICP-OES
method was developed for quantification of intracellular
platinum, i.e. the key element in cisplatin. MK571, an
inhibitor for efflux transporter, served as a positive control.
MK571 at different concentration was applied onto the
cultures to test the efficiency in accumulating intracellular
platinum: the maximal effect was up to ∼35 or ∼25% in
cultured A549 or A549-DDP cells, respectively, as compared
with control group (Figure 1A). The applied YPFS increased
intracellular platinum in a dose-dependent manner (Figure 1B),
similar to that of MK571. The robust effect of YPFS in increasing
intracellular platinum, within 3 h, was up to 70 and 50% in
cultured A549 and A549-DDP cells, respectively (Figure 1B).
The results indicated that YPFS could increase accumulation of
intracellular cisplatin in cultured A549 and A549-DDP cells in a
fast-onset manner.
The potentiating effect of YPFS in cytotoxicity of cisplatin
in cultured A549 and A549-DDP cells was determined.
Cisplatin at 20 μM increased the rate of cytotoxicity up to
∼43% for A549 cells and ∼27% for A549-DDP cells.
Meanwhile, cisplatin at 2.5 μM did not show any
cytotoxicity (Figure 2A). Thus, cisplatin at 2.5 μM without
toxicity was applied onto cultured A549, or A549-DDP, cells
in present or absent of YPFS for 24 h, as to determine the
FIGURE 2 | YPFS potentiates cytotoxic activity of cisplatin in cultured A549 and A549-DDP cells. (A): The cytotoxic activity of cisplatin against cultured A549/A549-
DDP cells (B): Synergy of YPFS and cisplatin in cytotoxic activity in cultured A549 cells. (C): Synergy of YPFS and cisplatin in cytotoxic activity in cultured A549-DDP cells.
A549/A549-DDP cells in a logarithmic phase were seeded (5,000/well) in 96-well plates and allowed to adhere overnight. Cells were then treated with drugs for 48 h.
Cisplatin at 2.5 µM (non-toxic dose) was co-applied with YPFS to test the synergistic effect in cell viability. MTT assay was applied to determine the cytotoxic
activity. Values are expressed as % of increase, as compared to control group (no drug), in mean ± SEM, n  3. * or #, p < 0.05, ** or ##, p < 0.01, *** or ###, p < 0.001.
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synergy in cell viability. YPFS by itself at high concentration
showed toxicity in the cultures (Figures 2B,C). The co-
applied YPFS showed synergy in potentiating the toxicity
of cisplatin at 2.5 μM (a non-toxic dose) in a dose-dependent
manner. The cytotoxicity of YPFS accompany with cisplatin
was increased up to four folds in cultured A549 cells
(Figure 2B). Similar potentiating effect of YPFS with
cisplatin was found in cultured A549-DDP cells, over two
folds as that of YPFS only (Figure 2C).
Yu Ping Feng San Suppresses Glutathione
S-transferase and ATPase
The level of GST activity was evaluated in cultured A549 and
A549-DDP cells, in the presence of YPFS for 48 h. The presence
of YPFS alone in the cultures decreased the activity of GST dose-
dependently: the effects were ∼30% in A549 cells and ∼40% in
A549-DDP cells (Figure 3A). The decreased GST activity might
be due to two reasons, i.e. inhibition of GST activity or reduction
of GST protein expression. YPFS was directly applied onto the cell
lysates, and then GST activity was inhibited (Figure 3B). In
addition, the expressions of transcripts encoding different members
of GSTs, e.g. GSTPi1 and GSTM1, weremeasured by real-time PCR.
The presence of YPFS effectively decreasedGSTPi1 expression, up to
∼55 and ∼20% of decrease in cultured A549 and A549-DDP cells,
respectively (Figure 3C). In parallel, YPFS decreased the expressions
of GSTM1 at ∼30% (A549) and at ∼20% (A549-DDP) in dose-
dependent manners (Figure 3D). Thus, YPFS could reduce both
expression and activity of GSTs, and which consequently reduced
the soluble form of cisplatin-conjugate, i.e. inhibiting extrusion of
cisplatin being pumped out of the cell.
To substantiate the role of YPFS in protein-drug interaction,
we performed the assay of ATPase activity. Verapamil, a substrate
for P-gp ATPase, was used to stimulate the enzymatic activity,
with or without 3 mg/ml YPFS, for 5 min. The activity of
verapamil-induced P-gp ATPase was suppressed by YPFS
(Figure 4A). In parallel, the suppressive effects of YPFS in
ATPase substrates, e.g., sulfasalazine for BCRP ATPase, NEM/
MSH for MRP1 ATPase, probenecid for MRP2 ATPase and
benzbromarone for MRP3 ATPase, were revealed (Figures
4B–E). The results suggested that YPFS could reduce ATPase
activity of the efflux transporters. Cisplatin is known to be efflux
transported by MRP2 via activating the ATPase activity. Here,
YPFS application was shown to decrease the MRP2 ATPase
activity, which therefore could affect the cisplatin transport, as
mediated by MRP2 ATPase. The result was in accord to the fast-
FIGURE 3 | YPFS suppresses GST activity and expression in cultured A549 and A549-DDP cells. (A): Cultured A549 and A549-DDP cells (40,000/well in 12-well
plate) were treated with YPFS for 48 h, and then the activity of GST was determined. (B): YPFS was applied to A549/A549-DDP cell lysate, and then GST activity was
measured. Values are expressed as unit of GST activity. (C and D): Cultured A549 and A549-DDP cells (120,000/well in 6-well plate) were treated with YPFS for 24 h,
and then mRNA expression levels of GSTPi1 (C) and GSTM1 (D) were determined using quantitative real-time PCR. GAPDH was used as an internal control for
normalization. Values are expressed as % of control (no drug), in mean ± SEM, n  3. * or #, p < 0.05, ** or ##, p < 0.01, *** or ###, p < 0.001.
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onset of YPFS in increasing intracellular accumulation of
cisplatin.
Yu Ping Feng San Suppresses Expressions
of P-glycoprotein, Breast Cancer
Resistance Protein and p65
In order to evaluate YPFS on expression of ATPase, cultured A549-
DDP cells were treated with YPFS for 48 h. Application of YPFS
induced a distinct downregulation of protein expressions of P-gp
and BCRP in dose-dependent manners, as compared with control
group in cultured A549-DDP cells. An ∼25% decrease of P-gp and
∼80% decrease of BCRP were identified at maximal response
(Figure 5). However, the effect of YPFS on protein expression of
P-gp and BCRP in A549 cells was minimal (data not shown).
NF-KB is known to activate a number of diverse genes in
responding to stimuli, and one of the major members of NF-KB,
p65, is known to be overexpressed in MDR cells. The role of p65
could exert pro-apoptotic or anti-apoptotic properties via
regulating various targets, e.g. expressions of pro-apoptotic
target Bax and anti-apoptotic target Bcl-2. The balance of Bax/
Bcl-2 directly affects the rate of apoptosis. An obvious decrease of
p65 expression in cultured A549 and A549-DDP cells was
observed in a dose-dependent manner in presence of YPFS:
the effects were reduced by ∼30% in A549 cells and ∼60% in
A549-DDP cells (Figure 6).
The apoptotic proteins were determined in YPFS-treated
cultures. The mRNA of Bcl-2 was decreased; while Bax mRNA
was increased in YPFS-treated cultured A549 and A549-DDP
cells (Figures 7A,B). The expression levels of Bcl-2 were
decreased by ∼40% (A549) and ∼20% (A549-DDP); while Bax
levels were increased by ∼220% (A549) and ∼150% (A549-DDP)
(Figures 7A,B). As a result, the ratio of Bax/Bcl-2 was increased
to ∼3.3 folds in cultured A549 cells and ∼1.7 folds in cultured
A549-DDP cells: both were in dose-dependent manners
(Figure 7C). The results suggested an alternative way of YPFS
in potentiating anti-cancer effect of cisplatin, targeting on p65
expression in cancer cells.
Prim-O-glucosylcimifugin is One of the
Active Ingredients in Yu Ping Feng San
Prim-O-glucosylcimifugin, a major ingredient derived from SR
and up to 0.882 mg/g in YPFS herbal extract, was subjected to
evaluate its effects in reversing cisplatin chemo-resistance. The
GST activities were decreased by ∼10% (A549) and ∼5% (A549-
DDP) (Figure 8A); the expression levels of GSTPi1 were
decreased by ∼33% (A549) and ∼18% (A549-DDP) (Figure
8B); the expression levels of GSTM1 were decreased by ∼70%
(A549) and ∼50% (A549-DDP) (Figure 8C), and cisplatin
accumulations were increased up to ∼56% (A549) and ∼30%
(A549-DDP) (Figure 8D). Moreover, prim-O-glucosylcimifugin
showed cytotoxic activity having ∼10% increase of cell death in
A549 and A549-DDP cells (Figures 8E,F). The cytotoxic
activities of prim-O-glucosylcimifugin, accompany with
cisplatin, were increased up to two folds (A549) and ∼1.6
folds (A549-DDP) as that of prim-O-glucosylcimifugin
(Figures 8E,F). The present results suggested that prim-O-
glucosylcimifugin could be an active ingredient in YPFS in
reversing the cisplatin drug resistance.
DISCUSSION
Drug resistance remains a challenge in cancer therapy. Our
previous study has found that YPFS could regulate p62/
TRAF6 signaling (Lou et al., 2016), WT1/MVP axis and
mTORC2/AKT signaling (Lou et al., 2018), which account the
anti-MDR effects and anti-cancer effects both in vivo and in vitro
models. To extend the function of YPFS in elevating the final
FIGURE 4 | YPFS suppresses ATPase activity. YPFS suppressed verapamil-stimulated P-gp ATPase (A), sulfasalazine-stimulated BCRP ATPase (B), NEM/GSH-
stimulated MRP1 ATPase (C), probenecid-stimulated MRP2 ATPase (D) and benzbromarone-stimulated MRP3 ATPase (E). The ATPase substrate was added to
plasma membranes, with or without 3 mg/ml YPFS, for 5 min. Then, Mg2+ATP (4 mM) was treated for further incubation, i.e. 20 min for P-gp, 10 min for BCRP, 60 min
for MRP1, 40 min for MRP2 and 60 min for MRP3. An identical reaction mixture containing 0.250 mM NaOV was assayed in parallel. Thus, ATPase activity
measured in the presence of NaOV represented non-ATPase activity, and which would be subtracted from the total activity measured in the various samples to yield
ATPase activity. The reaction was stopped by the addition of 10% SDS and liberation of inorganic phosphate was detected by colorimetric reaction with ascorbic acid in
ammonium molybdate solution. The amount of inorganic phosphate released by 1 mg ATPase within 1 min represents enzyme activity. Mean ± SEM, n  3.
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intracellular cisplatin concentration in a fast-onset manner, we
provided different lines of evidence of YPFS in reversing
cisplatin-resistance in lung cancer cell lines by reducing the
activities and expressions of ATP-binding cassette transporters,
and the levels of GSTs. In parallel, YPFS downregulated the
expression of p65 subunit of NF-κB leading to a higher ratio of
Bax/Bcl-2. Besides, prim-O-glucosylcimifugin was identified as
an active ingredient in YPFS to account in reversing cisplatin
drug resistance. The final outcome of YPFS application is to
synergize with cisplatin in triggering cell death, which therefore
supports the notion of employing a Chinese herbal decoction in
possible cancer treatment (Figure 9). In particular, this herbal
decoction has been used for hundreds of years with well-known
record of safety.
Lower bioavailability of cisplatin is another intractable
problem, which limits the efficacy of cisplatin in
chemotherapy. Many anti-cancer drugs are substrates for
efflux transporters. Application of efflux transporter inhibitor
is one of the strategies to reverse drug resistance; however, the
usages of inhibitor for efflux transporter has been proven
inefficient and severely toxic. None of these inhibitors have
been developed for clinical application (Yang and Liu, 2016).
The undeniable effect of Chinese medicine in reversing
multidrug resistance has been demonstrated. For example,
Sangeng mixture (Feng et al., 2003) and Shenghe powder
(Wang et al., 2007) have been reported to downregulate the
expression of P-gp transporter. In addition, Dahuang
Zhechong pill was shown to reduce ATP level by
suppressing the key metabolic enzymes, and the extract of
Rabdosia labtea was shown to alter GST activity (Guo et al.,
2020). As an outcome, these herbal extracts inhibited the
activity of efflux transporters. In accordance to this notion,
we provided several lines of evidence here to support the
efficacy of Chinese medicine in against drug resistance
during cancer therapy. The action mechanism of YPFS is to
decrease final activity of efflux transporters, and which
thereafter raises the bioavailability of drugs in cancer cells.
Consecutive activation of NF-κB is playing a role in immune
response, including drug resistance of cancer cell (Li et al., 2013;
Gong et al., 2017; Yu et al., 2018). Bcl-2 family, downstream
targets of NF-κB including pro-apoptotic (e.g., Bax) and anti-
apoptotic (e.g. Bcl-2) molecules, regulates the intrinsic pathway of
apoptosis (Rózalski et al., 2005; Yu et al., 2018). Here, YPFS was
shown to regulate p65 expression, as such to increase the ratio of
Bax/Bcl-2, as well as the rate of apoptosis. In mitochondrial
pathway, anti-apoptotic proteins of Bcl-2 family (e.g., Bcl-2) are
acting on outer mitochondrial wall to prevent liberation of
cytochrome c; while the pro-apoptotic proteins of Bcl-2 family
FIGURE 5 | YPFS suppresses protein expressions of P-gp and BCRP in
cultured A549-DDP cells. Cultured A549-DDP cells (120,000/well in 100-mm
plate) were treated with YPFS for 48 h. Cell lysates were collected, diluted to
equal protein concentration, and analyzed by western blotting.
Representative western blots are shown. Values are normalized using the
internal control GAPDH and expressed as % of control (untreated culture), in
mean ± SEM, n  3. * or #, p < 0.05, ** or ##, p < 0.01, *** or ###, p < 0.001.
FIGURE 6 | YPFS suppresses protein expression of p65 in cultured
A549 and A549-DDP cells. Cultured A549/A549-DDP cells (120,000/well in
100-mm plate) were treated with YPFS for 48 h. Cell lysates were analyzed by
means of western blotting as in Figure 4. Mean ± SEM are shown, n  3.
* or #, p < 0.05, ** or ##, p < 0.01, *** or ###, p < 0.001.
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(e.g., Bax) are migrating from cytosol to mitochondrial wall to
increase the liberation of pro-apoptotic factors, particularly
cytochrome c, resulting in cleavage of caspases, e.g., activating
caspase-3 and caspase-9 (Xiong et al., 2016). In line to this notion,
the role of YPFS in upregulating cleaved-caspase-3 and cleaved-
caspase-9 have been illustrated (Lou et al., 2016). Here, we further
provided evidence in supporting the regulation of YPFS in
signaling of caspase-3 and caspase-9. Thus, the regulation of
YPFS in intrinsic apoptotic pathway could serve as another underlying
mechanism of YPFS in potentiating the chemosensitivity of cisplatin
in cancer cells.
Prescribing of herbal formulae in treatment and prevention
of diseases has been a key part of TCM practice, apart from the
use of acupuncture and other manipulation treatments. The
accumulation of experience gained over thousands of years has
provided current application of TCM in situations, where
conventional medicine has encountered difficulty, such as
formation of drug resistance in chemotherapy of cancers,
chronic diseases, and infections among other ailments.
Chinese herbal medicine exhibits “multi-herb and multi-
target” manifestation, which can be partially explained for
its bi-directional actions and multi-targeting mechanisms.
For example, pro- and anti-inflammatory effects of YPFS
have been reported under different scenarios (Lee et al.,
2007; Li et al., 2007; Du et al., 2013). The present
investigations have provided another example of YPFS in
having bi-directional effects. Apoptosis is initiated via
intrinsic and extrinsic pathways. The enzyme dysregulating
production of reactive oxygen species (ROS) changes cellular
redox balance, and thus results in chemoresistance (Guo et al.,
2020). ROS, a highly active molecule, has dual roles in accord to
its level, i.e. normal level of ROS regulates the oxidative state for
cell protection, but abnormal level of ROS increases the toxicity
threshold resulting in DNA damage. The abnormal production
of ROS leads to NF-KB translocation into nucleus and initiate
pro-survival gene expression, which is one of the major causes
for drug resistance (Parajuli et al., 2013). A previous report
demonstrated that YPFS could potentiate cisplatin in
enhancing ROS level in cultured lung cancer cells, leading to
increase rate of apoptosis, whereas YPFS alone showed no effect
in ROS production (Lou et al., 2016). Thus, the effects on ROS
production in cisplatin-treated cultures could illustrate another
bi-directional regulation of YPFS.
The synergistic effect of TCM could be identified in many
cases, e.g., an 800-years old herbal decoction Dangui Buxue Tang
having AR and Angelicae Sinensis Radix in a weight ratio of 5:1,
produced better solubility and stability of the active ingredients,
and the best biological activities in stimulating estrogenic
responses, immunological responses, bone development and
hematopoiesis function (Dong et al., 2006; Zheng et al., 2010).
The present investigation supports the synergistic aspects of
combined herbal ingredients in which the AR-derived
calycosin and formononetin in YPFS could up-regulate activity
of efflux transporter ATPase, and additionally compete the
binding site of efflux transporters with cisplatin. Synergistic
regime of calycosin, or formononetin, with cisplatin was found
to elevate cisplatin accumulation in A549 cell resulting in higher
apoptotic rate (Du, 2014). Thus, calycosin and formononetin
within YPFS could be developed as competitive inhibitors for
cisplatin in reversing the drug resistance. In addition to regulate
GST, prim-O-glucosylcimifugin has been shown to exert anti-
inflammation (Zhou et al., 2017), anti-allergic (Jia et al., 2019)
and anti-cancer (Gao et al., 2019) effects. By having these lines
of evidence, YPFS has provided us a strong motivation to
develop the chemotherapeutic combined regime for anti-cancer
treatment.
FIGURE 7 | YPFS alters gene expressions of Bax and Bcl-2 in cultured A549 and A549-DDP cells. Cultured A549/A549-DDP cells (120,000/well in 6-well plate)
were treated with YPFS for 24 h. The expression levels of target proteins were revealed by quantitative real-time PCR. The transcript levels of Bax and Bcl-2 in cultured
A549 (A) and A549-DDP cells (B). Bax/Bcl-2 ratio (C) in cultured A549 and A549-DDP cells. Values are in mean ± SEM, n  3. * or #, p < 0.05, ** or ##, p < 0.01, *** or ###,
p < 0.001.
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The integrative approach of YPFS could remarkably potentiate
the effect of cisplatin within a short period of time viamodulating
the effects on GSTs and efflux transporter ATPases. Besides, the
effects of YPFS in regulating intrinsic apoptotic signaling,
including downregulation of p65 and upregulation of Bax/Bcl-
2 ratio, were demonstrated here. This is an example of utilizing
integrative medicine approach for difficulty cases, such as drug-
resistance of cancer cell. Here, prim-O-glucosylcimifugin was
identified as an active ingredient in YPFS to reverse cisplatin
chemo-resistance. The aforementioned findings provided an
FIGURE 8 | Identification of prim-O-glucosylcimifugin as an active ingredient of YPFS in reversing cisplatin chemo-resistance. Prim-O-glucosylcimifugin (3 and 10 µM)
were applied onto cultured A549 and A549-DDP cells. Assays of GST activity (A), gene expression of GSTPi1 (B) and GSTM1 (C), measurement of intracellular platinum (D),
and cytotoxic activity (E, F) were performed and analyzed as described in Figures 1-3. Values are in mean ± SEM, n  3. * or #, p < 0.05, ** or ##, p < 0.01, *** or ###, p < 0.001.
FIGURE 9 | Model of YPFS in tracking the cisplatin-resistance in a fast-onset manner in lung cancer cells. YPFS reduces the activities and expressions of ATP-
binding cassette transporters and the levels of GSTs, consequently increases intracellular cisplatin in A549/A549-DDP cells. In parallel, YPFS downregulates the
expression of p65 subunit of NF-κB leading to a higher ratio of Bax/Bcl-2. Finally, YPFS synergize with cisplatin in triggering cell death.
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understanding of the fast-onset action of YPFS in chemotherapy.
The attractive identification of YPFS as a chemosensitizer in both
in vitro and in vivo supports possible clinical application of
this herbal medicine in cancer therapy. In line to this notion,
AR showed anti-tumorigenic effects in vivo. The reduction of
tumor volume, as well as pro-apoptotic and anti-proliferative
effects, in HT-29 nude mice xenograft, treated with AR,
was comparable with that produced by the conventional
chemotherapeutic drug 5-fluorouracil (5-FU) (Tin et al.,
2007). In the same investigation, the side effects (body
weight drop and mortality) associated with the drug combo
5-FU and oxaliplatin were not induced by AR. These results
indicate that AR could be an effective chemotherapeutic agent in
colon cancer treatment, which may also be used as an adjuvant
in combining with other orthodox chemotherapeutic drugs
to reduce the side effects of cancer drugs. In addition, AMR
(Ruqiao et al., 2020) and SR (Yang et al., 2020) were also found
to possess anti-tumor activity. In conclusion, both YPFS and its
single herbal ingredients offer potential for further development
of new effective products for integrative medical treatment of
cancers.
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